logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls/Updates
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
    • 28 DEC 2021

    PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a 36-month stability study of the cells from its Master Cell Bank (MCB). These cells will be encapsulated and then used

    Read more →
    • Posted in
    • News
    • 15 DEC 2021

    PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the financial results for its second quarter ended October 31, 2021, and provided an overview of recent operational highlights (PharmaCyte’s Fiscal Year begins May 1 and ends

    Read more →
    • Posted in
    • News
    • 08 DEC 2021

    PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

    LAGUNA HILLS, CA, December 8, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of an additional, more detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the

    Read more →
    • Posted in
    • News
    • 30 NOV 2021

    PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

    LAS VEGAS, November 30, 2021–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the commencement of a pivotal study to determine if the treatment PharmaCyte uses for locally

    Read more →
    • Posted in
    • News
    • 12 NOV 2021

    PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation

    LAS VEGAS, NV, November 12, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material that makes up its CypCaps™ pancreatic cancer product does not cause skin irritation. PharmaCyte’s Chief

    Read more →
    • Posted in
    • News
    • 27 SEP 2021

    PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced further results from a third test of biocompatibility of its CypCaps™ product candidate for pancreatic cancer. The tests results showed that the empty capsule material is

    Read more →
    • Posted in
    • News
    • 21 SEP 2021

    PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

    LAGUNA HILLS, CA, September 21, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of a second U.S. Food and Drug Administration (FDA)-required test of biocompatibility of its CypCaps product for pancreatic

    Read more →
    • Posted in
    • News
    • 16 SEP 2021

    PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

    LAGUNA HILLS, CA, September 16, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the first test results of the biocompatibility studies of its CypCaps™ clinical trial product candidate. These results were from an

    Read more →
    • Posted in
    • News
    • 08 SEP 2021

    PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

    LAGUNA HILLS, CA, September 8, 2021 (BUSINESS WIRE) – PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference to be held

    Read more →
    • Posted in
    • News
    • 31 AUG 2021

    PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

    LAGUNA HILLS, CA, August 31, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its clinical trial product, CypCaps™, remains stable and active at 18 months after completing the 18-month timepoint of ongoing

    Read more →
    • Posted in
    • News
  • 1
  • 2
  • 3